@article{Drake_T-2021_45562,
title = {Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort:a matched, prospective cohort study},
author = {Drake, T. and Fairfield, C. and Pius, R. and Knight, S. and Norman, L. and Girvan, M. and Hardwick, H. and Docherty, A. and Thwaites, R. and Openshaw, P. and Baillie, J. and Harrison, E. and Semple, M. and ISARIC4C Investigators},
month = {jul},
year = {2021},
abstract = {Background: Early in the pandemic it was suggested that pre-existing use of non-steroidal anti-inflammatory drugs (NSAIDs) could lead to increased disease severity in patients with COVID-19. NSAIDs are an important analgesic, particularly in those with rheumatological disease, and are widely available to the general public without prescription. Evidence from community studies, administrative data, and small studies of hospitalised patients suggest NSAIDs are not associated with poorer COVID-19 outcomes. We aimed to characterise the safety of NSAIDs and identify whether pre-existing NSAID use was associated with increased severity of COVID-19 disease.},
pages = {E498-E506},
volume = {3},
issue = {7},
journal = {The Lancet Rheumatology},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S2665-9913(21)00104-1},
}
